Sequential treatment strategy for rheumatoid arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a sequential treatment approach for rheumatoid arthritis (RA) that begins with a TNF inhibitor for 12 weeks to control inflammation, followed by the use of abatacept, a targeted biological DMARD. The study aims to determine the efficacy of this strategy in patients who have not achieved treatment targets with conventional synthetic DMARDs. Participants must be ACPA positive and have been on methotrexate or leflunomide for at least three months. The trial will assess the reduction of auto-antibodies and overall disease management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged between 18 or above
* Rheumatoid arthritis according to ACR-EULAR 2010 (American College of Rheumatology-European League Against Rheumatism)
* ACPA positive
* Under methotrexate or leflunomide treatment for at least 3 months
* DAS28-CRP\>3.2 under methotrexate or leflunomide calculated with CRP dated less than 7 days from baseline
* Escape under synthetic background treatment defined by an elevation of C-reactive protein (CRP) (CRP\> 5mg/L ) or Erythrocyte sedimentation rate (ESR) (for men: \> age in years/2 ; for women: \> age (+10) /2)) within the last 6 months before baseline
* Targeted DMARDs (biological and targeted synthetic DMARDs) naïve
* Indication for a TNF inhibitor

Exclusion Criteria:

* Subject unable to read or/and write
* Planned longer stay outside the region that prevents compliance with the visit plan
* Subject unable to sign informed consent form
* Subject not covered by public health insurance
* Dementia
* Fibromyalgia
* Contra-indications to TNF inhibitor and/or Abatacept
* Absence of tuberculosis screening in the previous 3 months before baseline
* Patient with untreated active tuberculosis
* Patient who cannot be followed during 48 weeks
* Drug addiction, addiction to alcohol
* Protected populations according to the French Public Health Code Articles L1121-5,6,8 (For example, pregnant, parturient or lactating women, prisoners, adults under guardianship or otherwise unable to consent).
* Women of child bearing potential, unless they are using an effective method of birth control
* Patient under law protection
* Prisoners
* Subject who are in a dependency or employment with the sponsor or the investigator
* Participation in another interventional clinical trial or administration of an investigational product within the last 4 weeks before the screening date
* Subject with moderate to severe heart failure (class 3 or class 4 cardiac disease as defined by the New York Heart Association Functional Classification)
* Patients had a history of chronic obstructive pulmonary disease (COPD) and heavy smoking
* Patients had a planned surgical procedure at least 30 days before the screening day
* Known allergy or intolerance to an anti-TNF therapy
* Hypersensitivity to the Abatacept or to any of its excipients
* Patient with untreated active hepatitis B
* Patient vaccinated with a live vaccine within 30 days prior to screening
* Patients with an Inflammatory Bowel Disease (IBD) (loss of chance if switching from an anti-TNF to abatacept)

Where it's running

• Centre Hospitalier Universitaire de Montpellier
  Montpellier, France, France Recruiting
• CHU Bordeaux groupe Pellegrin
  Bordeaux, France Recruiting
• CHU de Brest La Cavale Blanche
  Brest, France Recruiting
• CHD Vendée
  La Roche-sur-Yon, France Recruiting
• CH du Mans
  Le Mans, France Recruiting
• CHU de Nantes
  Nantes, France Recruiting

Study contacts

• Study coordinator: Jacques MOREL, MD-PhD
• Email: j-morel@chu-montpellier.fr
• Phone: 467338710

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Telitacicept for difficult-to-treat rheumatoid arthritis

  This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.

  Recruiting Phase 2 Peking University People's Hospital · Hefei, Anhui and 46 other locations · NCT07796516

• PTC844 in people with active rheumatoid arthritis

  This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.

  Recruiting at 6 sites Phase 2 PTC Therapeutics · Chandler, Arizona and 25 other locations · NCT07779616

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

• IV sarilumab for adults with rheumatoid arthritis

  This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.

  Recruiting at 12 sites Phase 1/2 Sanofi · Centennial, Colorado and 11 other locations · NCT07704580

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.